Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.60 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.60 |
| ▸ | ATM | Q13315 | 1/20 | 0.53 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.51 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | CCNC | P24863 | 1/20 | 0.50 |
| ▸ | CDK8 | P49336 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | XDH | P47989 | 4/20 | 0.48 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.47 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.47 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3730017 | 0.87 | CYP11B1 (0.56) | CYP11B1CYP11B2ATMCYP2A6S1PR1 | |
| SCHEMBL640338 | 0.87 | CYP2C9 (0.59) | CYP11B1CYP11B2HDAC1CCNCCDK8 | |
| SCHEMBL3715051 | 0.85 | ATM (0.69) | CYP11B1CYP11B2ATMCYP2A6S1PR1 | |
| SCHEMBL1056598 | 0.85 | CYP11B1 (0.54) | CYP11B1CYP11B2ATMCYP2A6S1PR1 | |
| SCHEMBL25002964 | 0.84 | CYP11B2 (0.63) | CYP11B1CYP11B2ATMCYP2A6S1PR1 | |
| SCHEMBL25002936 | 0.84 | CYP11B1 (0.64) | CYP11B1CYP11B2ATMCYP2A6S1PR1 | |
| SCHEMBL4592444 | 0.83 | CYP11B1 (0.62) | CYP11B1CYP11B2ATMCYP2A6MAPT | |
| SCHEMBL5326283 | 0.83 | CYP11B1 (0.79) | CYP11B1CYP11B2ATMCYP2A6HDAC1 | |
| SCHEMBL2906199 | 0.83 | CYP11B1 (0.62) | CYP11B1CYP11B2ATMCYP2A6S1PR1 | |
| SCHEMBL9008962 | 0.83 | CYP11B1 (0.61) | CYP11B1CYP11B2ATMCYP2A6CDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102596944-B | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-08-26 | — | — | CN | disclosed |
| US-20150183773-A1 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-02 | — | — | US | disclosed |
| US-20150183773-A1 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-02 | — | — | US | disclosed |
| US-20150183773-A1 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-07-02 | — | — | US | disclosed |
| CN-104744452-A | Substituted piperidines | Bayer Pharma AG | 2015-07-01 | — | — | CN | disclosed |
| US-8987248-B2 | Substituted piperidines as Par-1 antagonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987248-B2 | Substituted piperidines as Par-1 antagonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987248-B2 | Substituted piperidines as Par-1 antagonists | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2015-03-24 | — | — | US | disclosed |
| CN-102482270-B | Substituted piperidines | BAYER IP GMBH | 2015-02-25 | — | — | CN | disclosed |
| US-20130252948-A1 | Substituted piperidines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| WO-2010136138-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136127-A1 | SUBSTITUTED 3-(1,2,4-OXADIAZOL-5-YL)-5-PHENYLPIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| WO-2010136144-A1 | SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305111-A1 | SUBSTITUTED PIPERIDINES | Bayer Schering Pharma (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305111-A1 | SUBSTITUTED PIPERIDINES | Bayer Schering Pharma (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20100305111-A1 | SUBSTITUTED PIPERIDINES | Bayer Schering Pharma (DE) | 2010-12-02 | — | — | US | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER HEALTHCARE AG (DE) | 2009-12-10 | — | — | US | disclosed |
| WO-2009068214-A2 | HETEROARYL-SUBSTITUTED PIPERIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306139-A1 | HETEROARYL-SUBSTITUTED PIPERIDINES | VHL, PIGO, PLIN3 | CYP11B1 107/4885CYP11B2 60/4885ATM 4056/4885 |
| US-20100305111-A1 | SUBSTITUTED PIPERIDINES | VHL, PIR, PTGIS | CYP11B1 1246/4885CYP11B2 922/4885ATM 4039/4885 |
| US-20130252948-A1 | Substituted piperidines | VHL, PIR, PTGIS | CYP11B1 1246/4885CYP11B2 922/4885ATM 4039/4885 |
| US-20150183773-A1 | Substituted piperidines | VHL, PIR, PIGO | CYP11B1 680/4885CYP11B2 417/4885ATM 4100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.